Lantern Pharma Inc. is an artificial intelligence‑focused biotechnology company dedicated to discovering and developing cancer therapies by transforming oncology drug discovery and development. The company’s core activity revolves around its proprietary RADR® platform, which integrates over 200 billion oncology‑focused data points drawn from multi‑omic datasets, drug‑tumor interactions, clinical records, scientific literature and mechanistic pathway data, and…
Lantern Pharma Inc. is an artificial intelligence‑focused biotechnology company dedicated to discovering and developing cancer therapies by transforming oncology drug discovery and development. The company’s core activity revolves around its proprietary RADR® platform, which integrates over 200 billion oncology‑focused data points drawn from multi‑omic datasets, drug‑tumor interactions, clinical records, scientific literature and mechanistic pathway data, and applies more than 200 machine‑learning algorithms to identify biomarker‑driven small‑molecule candidates and to rescue previously abandoned compounds. Lantern Pharma advances a pipeline that includes three clinical‑stage small‑molecule drug candidates—LP‑300, LP‑184, and LP‑284—and an antibody‑drug conjugate (ADC) program, while also developing a wholly‑owned subsidiary, Starlight Therapeutics, to focus on central nervous system indications for LP‑184 (branded STAR‑001).
Lantern Pharma Inc. generates revenue primarily through research collaborations, licensing agreements, and grant funding with pharmaceutical and academic partners. Notable collaborations include a May 2021 agreement with Actuate Therapeutics to utilize the RADR® platform for biomarker discovery, a February 2023 collaboration with TTC Oncology to accelerate development of the drug candidate TTC‑352, and a mid‑2024 partnership with Oregon Therapeutics to optimize the PDI inhibitor XCE853 using AI‑driven biomarker identification. The company also receives licensing revenue and milestone payments from arrangements such as the reacquisition of LP‑100 from Allarity Therapeutics and in‑licensed patents from AF Chemicals and BioNumerik Pharmaceuticals. Looking ahead, Lantern Pharma intends to monetize its AI platforms—RADR® and withZeta. AI—through subscription, access, and service models offered to biopharma companies, researchers, and drug developers. At present, the company has no approved commercial products and therefore does not derive revenue from product sales.
Lantern Pharma Inc. occupies a distinctive niche at the intersection of biotechnology and artificial intelligence‑driven drug development, differentiating itself through an AI‑enabled strategy that both rescues historical drug candidates and designs de‑novo compounds guided by biomarker signatures. The company competes with AI‑focused drug developers such as AbCellera, Atomwise, InSilico Medicine, Iktos, Verge Genomics, Recursion Pharmaceuticals, Schrodinger, and Roivant Sciences, as well as with oncology‑focused clinical‑stage companies including Candel Therapeutics, Pyxis Oncology, Foghorn Therapeutics, Prelude Therapeutics, Warewolf Therapeutics, Xilio Therapeutics, Ikena Oncology, Atossa Therapeutics, Elevation Oncology, and Bolt Biotherapeutics. Its competitive advantages stem from the scale and depth of the RADR® platform—over 200 billion data points and a library of 200+ ML algorithms—which enables rapid identification of biologically relevant genomic signatures and prediction of drug response, reducing the typical timeline from AI insight to first‑in‑human trials to two to three years and the associated cost to approximately $1.0‑$2.5 million per program. Additionally, Lantern Pharma’s pipeline benefits from multiple orphan drug, rare pediatric disease, and Fast Track designations from the FDA for indications such as glioblastoma, triple‑negative breast cancer, mantle cell lymphoma, and high‑grade B‑cell lymphoma, providing regulatory incentives and market exclusivity that further de‑risk development.
Lantern Pharma Inc. collaborates with a diverse set of biopharma partners, academic institutions, and research organizations to advance its drug candidates and AI platforms. Specific collaborators named in the filing include Actuate Therapeutics, TTC Oncology, Oregon Therapeutics, the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Georgetown University, the Danish Cancer Society‑Research Center, and the Greehey Children’s Cancer Research Institute. The company’s therapeutic focus spans multiple oncology indications, targeting patient populations in non‑small cell lung cancer (particularly never‑smoker adenocarcinoma), triple‑negative breast cancer, glioblastoma and other central nervous system cancers, pancreatic cancer, hematologic malignancies such as mantle cell lymphoma and diffuse large B‑cell lymphoma, and rare pediatric tumors like atypical teratoid rhabdoid tumors. Ultimately, the company’s therapies are intended to serve cancer patients who stand to benefit from biomarker‑driven, precision‑medicine approaches that match the right drug to the right patient.
Sectors:Healthcare · TechnologySector rationaleThe company's primary business is the discovery and development of cancer therapies, maintaining a pipeline of clinical-stage small-molecule drug candidates (LP-300, LP-184, LP-284) and an ADC program. A secondary sector of Technology is justified because the company explicitly intends to monetize its AI platforms (RADR and withZeta.AI) through subscription and access models sold to external biopharma companies and researchers.Industries:BiotechnologyHealthcarePrimaryLantern Pharma is a biotechnology company that researches and develops cancer therapies, including small-molecule candidates (LP-300, LP-184, LP-284) and antibody-drug conjugates. Its revenue is derived from research collaborations, licensing agreements, and milestone payments, which is characteristic of clinical-stage biotech developers.Healthcare ITTechnologySecondaryThe company develops and intends to monetize proprietary AI platforms, RADR and withZeta.AI, through subscription and service models specifically for biopharma companies and drug developers to assist in biomarker discovery and drug development.Classified using BQ-MICSCIK: 0001763950
Investment Thesis
▲ Bull case
Lantern Pharma's LP-300 program in the HARMONIC trial demonstrates a compelling duration-dependent efficacy signal in the L858R NSCLC subgroup, with median PFS of 8.9 months for patients receiving up to six cycles, significantly outperforming historical chemotherapy benchmarks of 4.2–5.5 months and showing a favorable tolerability profile compared to the current standard amivantamab plus chemotherapy, which carries substantially higher rates of serious adverse events and treatment discontinuations; this differentiated safety and efficacy profile positions LP-300 as a potential best-in-class option for heavily pre-treated, biomarker-defined patients who prioritize quality of life and sustained treatment adherence, creating a clear pathway for accelerated FDA approval and partnership interest given the large unmet need in this 40% subset of EGFR-mutated NSCLC patients globally.
The company's strategic decision to commercialize RADR AI platform modules via a freemium model represents an underappreciated near-term catalyst that could generate meaningful revenue streams while simultaneously enhancing the platform's proprietary data moat through user-contributed real-world oncology data, with management explicitly noting the intent to aggregate additional data to strengthen the platform's value, and given the RADR platform's expansion to approximately 200 billion oncology data points and its leadership in BBB permeability prediction—ranked in five of the top ten positions on the Therapeutic Commons leaderboard—this dual approach of internal pipeline acceleration and external monetization could unlock significant shareholder value beyond near-term clinical milestones, particularly as agentic AI capabilities emerge to transform the platform from an analytical tool into an autonomous development partner.
Lantern Pharma's LP-184 molecule holds four rare pediatric disease designations and two fast track designations, creating eligibility for up to four priority review vouchers upon approval in pediatric indications, each of which can be marketed and sold for $100 million to $150 million, representing a potential non-dilutive funding source of up to $600 million that management highlighted as a key value driver, yet the market appears to be underestimating the near-term monetization potential of these vouchers, especially given the recent Johns Hopkins data confirming high sensitivity of rare pediatric brain tumors to LP-184, which supports planned trials and de-risks the path to voucher eligibility through Starlight Therapeutics' wholly-owned subsidiary structure.
Lantern Pharma's LP-300 program in the HARMONIC trial demonstrates a compelling duration-dependent efficacy signal in the L858R NSCLC subgroup, with median PFS of 8.9 months for patients receiving up to six cycles, significantly outperforming historical chemotherapy benchmarks of 4.2–5.5 months and showing a favorable tolerability profile compared to the current standard amivantamab plus chemotherapy, which carries substantially higher rates of serious adverse events and treatment discontinuations; this differentiated safety and efficacy profile positions LP-300 as a potential best-in-class option for heavily pre-treated, biomarker-defined patients who prioritize quality of life and sustained treatment adherence, creating a clear pathway for accelerated FDA approval and partnership interest given the large unmet need in this 40% subset of EGFR-mutated NSCLC patients globally.
The company's strategic decision to commercialize RADR AI platform modules via a freemium model represents an underappreciated near-term catalyst that could generate meaningful revenue streams while simultaneously enhancing the platform's proprietary data moat through user-contributed real-world oncology data, with management explicitly noting the intent to aggregate additional data to strengthen the platform's value, and given the RADR platform's expansion to approximately 200 billion oncology data points and its leadership in BBB permeability prediction—ranked in five of the top ten positions on the Therapeutic Commons leaderboard—this dual approach of internal pipeline acceleration and external monetization could unlock significant shareholder value beyond near-term clinical milestones, particularly as agentic AI capabilities emerge to transform the platform from an analytical tool into an autonomous development partner.
Lantern Pharma's LP-184 molecule holds four rare pediatric disease designations and two fast track designations, creating eligibility for up to four priority review vouchers upon approval in pediatric indications, each of which can be marketed and sold for $100 million to $150 million, representing a potential non-dilutive funding source of up to $600 million that management highlighted as a key value driver, yet the market appears to be underestimating the near-term monetization potential of these vouchers, especially given the recent Johns Hopkins data confirming high sensitivity of rare pediatric brain tumors to LP-184, which supports planned trials and de-risks the path to voucher eligibility through Starlight Therapeutics' wholly-owned subsidiary structure.
Lantern Pharma's financial position remains precarious despite management's assertion of a 12-month operating runway, as the $19.7 million cash balance as of March 31, 2025 must cover ongoing R&D expenses, G&A costs, and the substantial financial burden of advancing multiple clinical programs simultaneously, including the FDA-cleared Phase 1b/2 trials for LP-184 in TNBC and STK11/KEAP1-mutant NSCLC, the HARMONIC trial expansion, and the planned STAR-001 CNS trial, with CFO David Margrave explicitly stating the need for additional funding in the near future as a key objective, highlighting that the current runway is contingent on maintaining strictly disciplined expenditures and does not account for potential delays, trial expansions, or partnership-related costs that could rapidly erode cash reserves before mid-2026.
The clinical data supporting LP-300's efficacy in the L858R NSCLC subgroup remains exploratory and based on small patient cohorts, with the HARMONIC trial's L858R-enriched cohort consisting of only 31 patients and the initial safety lead-in showing a 43% objective response rate derived from just seven patients, raising significant concerns about the reproducibility and statistical robustness of the observed duration-dependent PFS benefit, especially given the company's own forward-looking statements warning that observations in preclinical and emerging clinical studies do not ensure later success, and that clinical benefit observed to date may not be reproduced in larger or confirmatory studies, which poses a material risk to the thesis of LP-300 as a differentiated therapeutic option.
Lantern Pharma's reliance on its AI platform as a primary value driver faces substantial execution risks, as the commercialization of RADR modules via a freemium model is unproven in generating sustainable revenue, and the company's acknowledgment that it is "primarily focused on advancing our pipeline at this time" suggests that platform monetization may remain a secondary priority, potentially delaying or diluting the anticipated revenue stream, while the competitive landscape in AI-driven drug discovery is intensifying with larger players possessing greater data scale and resources, undermining the assumption that Lantern's 200 billion data point RADR platform will maintain its competitive edge or successfully attract sufficient external users to meaningfully strengthen the platform through user-contributed data.
Lantern Pharma's financial position remains precarious despite management's assertion of a 12-month operating runway, as the $19.7 million cash balance as of March 31, 2025 must cover ongoing R&D expenses, G&A costs, and the substantial financial burden of advancing multiple clinical programs simultaneously, including the FDA-cleared Phase 1b/2 trials for LP-184 in TNBC and STK11/KEAP1-mutant NSCLC, the HARMONIC trial expansion, and the planned STAR-001 CNS trial, with CFO David Margrave explicitly stating the need for additional funding in the near future as a key objective, highlighting that the current runway is contingent on maintaining strictly disciplined expenditures and does not account for potential delays, trial expansions, or partnership-related costs that could rapidly erode cash reserves before mid-2026.
The clinical data supporting LP-300's efficacy in the L858R NSCLC subgroup remains exploratory and based on small patient cohorts, with the HARMONIC trial's L858R-enriched cohort consisting of only 31 patients and the initial safety lead-in showing a 43% objective response rate derived from just seven patients, raising significant concerns about the reproducibility and statistical robustness of the observed duration-dependent PFS benefit, especially given the company's own forward-looking statements warning that observations in preclinical and emerging clinical studies do not ensure later success, and that clinical benefit observed to date may not be reproduced in larger or confirmatory studies, which poses a material risk to the thesis of LP-300 as a differentiated therapeutic option.
Lantern Pharma's reliance on its AI platform as a primary value driver faces substantial execution risks, as the commercialization of RADR modules via a freemium model is unproven in generating sustainable revenue, and the company's acknowledgment that it is "primarily focused on advancing our pipeline at this time" suggests that platform monetization may remain a secondary priority, potentially delaying or diluting the anticipated revenue stream, while the competitive landscape in AI-driven drug discovery is intensifying with larger players possessing greater data scale and resources, undermining the assumption that Lantern's 200 billion data point RADR platform will maintain its competitive edge or successfully attract sufficient external users to meaningfully strengthen the platform through user-contributed data.